DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Duffaud F, Blay JY, Mir O. et al.
Results of randomized, placebo (PL)-controlled phase II study evaluating
efficacy and safety of regorafenib (REG) in patients (pts) with metastatic
osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and
Unicancer.
ASCO. 2018 Abstract #11504
Access:
We do not assume any responsibility for the contents of the web pages of other providers.